Danaher Co. (NYSE:DHR) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Danaher Co. (NYSE:DHR - Free Report) by 11.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,677,032 shares of the conglomerate's stock after purchasing an additional 579,046 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.79% of Danaher worth $1,303,163,000 at the end of the most recent reporting period.3 Stocks Offering Strong Value and StabilitySeveral other large investors have also modified their holdings of the business. Norges Bank purchased a new position in Danaher during the fourth quarter worth about $2,130,740,000. Raymond James Financial Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $391,172,000. Two Sigma Advisers LP lifted its holdings in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares during the period. Capital World Investors grew its holdings in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the period. Finally, Point72 Asset Management L.P. increased its position in Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after purchasing an additional 1,107,998 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds. Danaher Price PerformanceDHR opened at $196.33 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock has a market capitalization of $140.51 billion, a P/E ratio of 37.18, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. The company's 50 day simple moving average is $196.69 and its 200-day simple moving average is $216.91. Danaher Co. has a one year low of $171.00 and a one year high of $281.70. Agilent Technologies Thrives From the Forever Chemicals CrackdownDanaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Sell-side analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year. Danaher Announces DividendThe firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's dividend payout ratio is 24.85%. Insider Buying and SellingWill Danaher stock hit new highs in 2024?In other news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders. Analysts Set New Price TargetsDHR has been the subject of a number of research analyst reports. Citigroup reissued a "buy" rating on shares of Danaher in a research report on Monday, April 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. reduced their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. UBS Group lowered their price target on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, StockNews.com upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $264.40.Read Our Latest Stock Analysis on DHRDanaher Company Profile (Free Report)Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.Read MoreFive stocks we like better than Danaher5 Top Rated Dividend Stocks to ConsiderHere's The Bull Case For Roku Stock With Double-Digit UpsideThe Role Economic Reports Play in a Successful Investment StrategySpotify Stock's Rally Still Has Legs To Run Higher Why Are These Companies Considered Blue Chips?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Danaher Right Now?Before you consider Danaher, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here